NEW YORK, NY / ACCESSWIRE / February 22, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
TLIS Shareholders Click Here: https://www.zlk.com/pslra-1/talis-biomedical-corporation-loss-submission-form?prid=23951&wire=1
BIIB Shareholders Click Here: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form-2?prid=23951&wire=1
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23951&wire=1
* ADDITIONAL INFORMATION BELOW *
Talis Biomedical Corporation (NASDAQ: TLIS)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Talis common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s February 2021 initial public offering.
Lead Plaintiff Deadline : March 8, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/talis-biomedical-corporation-loss-submission-form?prid=23951&wire=1
According to the lawsuit, documents that the Company issued in connection with its IPO failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis’s Emergency Use Authorization application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company’s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Biogen Inc. (NASDAQ: BIIB)
BIIB Lawsuit on behalf of: investors who purchased June 7, 2021 – January 11, 2022
Lead Plaintiff Deadline : April 8, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form-2?prid=23951&wire=1
According to the filed complaint, during the class period, Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration (“FDA”) that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer’s disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer’s patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019; and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC)
FENC Lawsuit on behalf of: investors who purchased May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline : April 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23951&wire=1
According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/689979/CLASS-ACTION-UPDATE-for-TLIS-BIIB-and-FENC-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders